Halozyme Therapeutics, the American biotechnology company collaborating with Janssen Biotech., Inc. to develop new formulations for drugs, has announced plans for a Phase I trial of a subcutaneous formulation of daratumumab in myeloma patients. Daratumumab is a monoclonal anti-CD38 antibody that is showing promise as a potential treatment for myeloma. It is currently administered by intravenous infusion. Using Halozyme’s proprietary drug delivery platform, ENHANZE™, daratumumab may be delivered in a smaller volume. The trial is expected to start recruitment soon.